Skip to main content

Thyroid Eye Disease clinical trials at UCLA

3 in progress, 2 open to eligible people

Showing trials for
  • Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

    open to eligible people ages 18 years and up

    The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

    Los Angeles, California and other locations

  • Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

    open to eligible people ages 18 years and up

    An open-label study for participants who are non-responders at end of the treatment period assessment (i.e., 15 weeks) in the VRND-001-101 (THRIVE) and VRDN-001-301 (THRIVE-2) pivotal studies

    Los Angeles, California and other locations

  • TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

    Sorry, in progress, not accepting new patients

    This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants. This international, Phase 3b/4 trial is being conducted to fulfill an FDA post-marketing requirement for a descriptive trial to evaluate the safety, efficacy and need for re-treatment of 3 different teprotumumab treatment durations for TED. In addition, serum samples from participants with a Baseline Clinical Activity Score (CAS) ≥3 will be evaluated for biomarkers of disease.

    Beverly Hills, California and other locations

Last updated: